Philip Morris International Inc. (PMI) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. PMI is a leading international tobacco company transitioning its portfolio toward smoke-free products (SFPs), including heat-not-burn (IQOS), e-vapor, and oral nicotine products (ZYN). The company operates in four geographical segments (Europe; SSEA, CIS & MEA; EA, AU & PMI DF; Americas) and a Wellness and Healthcare segment. In Q2 2024, PMI fully integrated the former Swedish Match segment results into its geographical segments.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | 2024 (YTD) | 2023 (YTD) | Change |
|---|---|---|---|
| Net Revenues | $18,261 million | $16,986 million | +7.5% |
| Operating Income | $6,489 million | $5,297 million | +22.5% |
| Net Earnings (Attributable to PMI) | $4,554 million | $3,563 million | +27.8% |
| Diluted EPS | $2.92 | $2.29 | +27.5% |
| Operating Cash Flow | $4,873 million | $2,487 million | +95.9% |
| Total Debt | $49.1 billion | $47.9 billion (Dec 31, 2023) | N/A |
| Cash and Cash Equivalents | $4,807 million | $3,060 million (Dec 31, 2023) | N/A |
Smoke-Free Performance: Smoke-free revenues (excluding Wellness & Healthcare) grew 17.5% to $6.8 billion. Oral product shipment volume increased 31.2%, driven by ZYN nicotine pouches. Heated Tobacco Unit (HTU) shipments increased 16.8%.
Material Changes vs. Prior Period
- Revenue Growth: Driven by favorable pricing (primarily combustible tobacco) and favorable volume/mix (driven by smoke-free products). Currency headwinds reduced reported revenue growth by approximately 3.3 percentage points.
- Profitability: Operating income growth was significantly aided by the absence of the $665 million goodwill impairment charge recorded in Q2 2023 (Wellness & Healthcare segment) and the $204 million South Korea indirect tax charge recorded in Q2 2023.
- Costs: Amortization of intangibles increased to $332 million (from $163 million in 2023) due to the reacquisition of IQOS commercialization rights in the U.S. from Altria Group, Inc. effective May 1, 2024.
- Equity Investments: Income from equity investments increased by $322 million, primarily due to a favorable fair value adjustment for investments in India and Sri Lanka.
Guidance, Outlook, and Risks
- 2024 Outlook: PMI expects full-year 2024 total shipment volume growth of 1% to 2%, driven by smoke-free products. Net cash provided by operating activities is expected to be approximately $11 billion. Capital expenditures are expected to be $1.3 billion to $1.4 billion.
- Effective Tax Rate: Estimated full-year 2024 effective tax rate is 21% to 22%, excluding discrete tax events.
- Key Risks & Contingencies:
- Regulatory: Ongoing FDA reviews for IQOS and ZYN products in the U.S. Renewal applications for IQOS exposure modification orders were filed; decisions were not issued prior to the July 2024 expiration date, though PMI believes it can continue marketing pending review.
- Geopolitical: Continued risks in Russia and Ukraine. Russian operations hold approximately $2.8 billion in assets. A petition for forced localization of PMI's Russian distributor was filed in July 2024.
- Litigation: New class actions filed in the U.S. in Q2 2024 regarding ZYN nicotine pouches (alleging addiction and marketing to minors). Long-standing Canadian litigation remains stayed under CCAA proceedings.
- Restructuring: $168 million in asset impairment and exit costs recorded in 2024, related to IQOS U.S. sourcing restructuring and the cessation of operations in Venezuela.
Investor Verification Checklist
- U.S. Market Transition: Verify the impact of the May 1, 2024, reacquisition of IQOS rights from Altria on U.S. revenue recognition and the associated increase in amortization expenses.
- Regulatory Status: Monitor the status of FDA renewal applications for IQOS and ZYN products, as well as the outcome of the D.C. Attorney General investigation into ZYN sales compliance.
- Geopolitical Exposure: Assess the potential financial impact of the forced localization petition against PMI's Russian distributor and the broader risks to the $2.8 billion in Russian assets.
- Wellness & Healthcare: Review the performance of the Vectura Fertin Pharma segment, which remains loss-making, and monitor for potential future impairment charges given the narrow margin of safety in its fair value assessment.
- Currency Impact: Evaluate the sensitivity of future earnings to fluctuations in the Egyptian pound, Japanese yen, and Russian ruble, which were significant headwinds in the first half of 2024.